patients are eager for participatory discussions and those who participate in those discussions demonstrate high rates of knowledge...

from the ASCO plenary june 1, 2019 there is a large volume of evidence that racial disparities exist in cancer outcomes and access to...

pre-ASCO highlights 2019 it’s that time of year again. the world of oncology is gathering in chicago this weekend for the american...

biosimilars aren’t coming, they’re here. in 2010 health canada published the HC Guidance document: information and submission...

a few weeks ago, I attended the canadian agency for drugs and technologies in health [CADTH] symposium in edmonton, AB. the opening...

the annual canadian agency for drug and technologes in health CADTH symposium was held in edmonton, alberta with nearly 700 professionals...

shifting the conversations. if the arrival of car-t has taught us anything, and it certainly has, it is that perhaps one of the major...

a rapid new wave of innovations in technologies and therapies in oncology continue to disrupt the landscape, and while these innovations...

with recent health canada approvals of two new car-t cell treatments [tisagenlecleucel in september 2018 and [axicabtagene ciloleuce] in...

last week i had the opportunity to attend the international experience exchange for patient organizations [IEEPO] in rome, italy.  the...

personalised medicine is widely considered as the way of the future for medicine, especially in cancer, where we are moving away from the...

as groundbreaking as car t-cell therapy is, it’s also incredibly complex and expensive to deliver. the rapid advances in and growth of...

the old adage says you can’t teach an old dog new tricks, but what about an outdated healthcare system. can we teach an old system to be...

what is car-t cell therapy? a  t-cell [so called because they develop in the thymus gland] is a type of white blood cell and it plays an...

immuno-oncology has been making headways over the last few years, from breakthrough therapy to standard of care and we are still only on...